Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

FDA Approves Intravesical Mitomycin for Recurrent, Low-Grade, Intermediate-Risk NMIBC

June 12th 2025

The FDA approved mitomycin intravesical solution for recurrnet, low-grade, intermediate-risk non–muscle-invasive bladder cancer.

Obrixtamig Plus Topotecan Could Address a Second-Line Need in SCLC

June 12th 2025

Obrixtamig combined with topotecan demonstrated favorable safety and early efficacy in relapsed/refractory SCLC.

FDA Grants Fast Track Designation to RAD101 for Imaging of Brain Metastases

June 12th 2025

The FDA granted fast track designation to RAD101 for imaging of cerebral metastases from various solid tumors, including leptomeningeal metastases.

FDA Approves Tablet Formulation of Zanubrutinib for B-Cell Malignancies

June 11th 2025

The FDA has approved a tablet formulation of zanubrutinib for use in all 5 approved indications of the capsule formulation.

Dr Gonzalez Velez on the Role of Tarlatamab As Second-Line Treatment For SCLC

June 11th 2025

Miguel Gonzalez Velez, MD, discusses the role of tarlatamab as a second-line treatment for small cell lung cancer.

Dr Pennell on the Significance of the FDA Approval of Taletrectinib for ROS1+ NSCLC

June 11th 2025

Nathan A. Pennell, MD, PhD, discusses the significance of the FDA approval of taletrectinib for ROS1-positive non-small cell lung cancer.

Dr Sabari on c-MET as a Potential Biomarker of Response in EGFR Wild-Type NSCLC

June 11th 2025

Joshua Sabari, MD, explains the rationale behind targeting c-MET in nonsquamous EGFR wild-type advanced NSCLC.

FDA Approves Taletrectinib for ROS1+ Advanced NSCLC

June 11th 2025

The FDA has approved taletrectinib for use in patients with ROS1-positive advanced non–small cell lung cancer.

Sacituzumab Tirumotecan Plus Tagitanlimab Receives Breakthrough Therapy Designation in China for First-Line, Nonsquamous NSCLC

June 11th 2025

China’s Center for Drug Evaluation granted breakthrough therapy designation to sacituzumab tirumotecan for nonsquamous non–small cell lung cancer.

Iopofosine I-131 Demonstrates Safety and Early Efficacy in Pediatric R/R High-Grade Glioma

June 11th 2025

Data from the phase 1 CLOVER-2 trial demonstrated the safety and activity of iopofosine I-131 in relapsed/refractory pediatric high-grade glioma.

Phase 1 Data Pave the Way for Further Investigation of IMA203 in Advanced Melanoma

June 11th 2025

Jason J. Luke, MD, FACP, discusses data for the PRAME-targeted TCR T-cell therapy IMA203 in advanced or metastatic melanoma.

DESTINY-Breast09 and Ongoing Trials Underscore Shifting ADC Landscape in HER2+ Breast Cancer

June 11th 2025

Hope S. Rugo, MD, discusses key considerations and unanswered questions arising from the DESTINY-Breast09 trial in HER2-positive breast cancer.

Dr Cristofanilli on the Potential Role of Serial ESR1 Mutation Monitoring in HR+/HER2-Negative Advanced Breast Cancer

June 10th 2025

Massimo Cristofanilli, MD, details the implications of serial ESR1 mutation monitoring using ctDNA in HR-positive/HER2-negative advanced breast cancer.

Dr Mayer on Imlunestrant in HR+/HER2-Negative Advanced Breast Cancer Following Prior Endocrine Therapy

June 10th 2025

Erica L. Mayer, MD, MPH, discusses the use of imlunestrant in HR+, HER2-negative advanced breast cancer following prior endocrine therapy.

RLY-2608 Plus Fulvestrant Demonstrates Efficacy in PIK3CA-Mutated, HR+/HER2– Advanced Breast Cancer

June 10th 2025

Sarah Sammons, MD, discusses data from the phase 1 ReDiscover trial of RLY-2608 plus fulvestrant in HR-positive, HER2-negative breast cancer.

Elacestrant Displays Potential as Combination Backbone in ER+ Breast Cancer After CDK4/6 Inhibition

June 10th 2025

Elacestrant-based combinations were safe and displayed preliminary efficacy in ER-positive/HER2-negative advanced breast cancer.

FDA Grants Fast Track Designation to PHST001 for Ovarian Cancer

June 9th 2025

The FDA granted fast track designation to PHST001 for patients with ovarian cancer.

SERENA-6 Introduces Potential New Paradigm of Early ESR1 Mutation Detection to Delay Progression in HR+ Breast Cancer

June 9th 2025

Erica L. Mayer, MD, MPH, discusses the implications of data from the SERENA-6 trial for ESR1 testing in hormone receptor–positive breast cancer.

Curiosity and Compassion Propel Lung Cancer Pioneer Ramalingam to TIME100 Health 2025 List

June 9th 2025

Suresh S. Ramalingam, MD, FACP, FASCO, highlights his journey in the lung cancer field, leading up to his recognition on the TIME100 Health 2025 list.

Five Under 5: Top Oncology Videos for the Week of 6/1

June 8th 2025

The top oncology videos of the week for the week of June 1, 2025, including updates from the 2025 ASCO Annual Meeting.